title: Patient satisfaction with primary care office-based buprenorphine/naloxone treatment.
abstract: BACKGROUND
  Factors associated with satisfaction among patients receiving primary care-based buprenorphine/naloxone are unknown.
  
  
  OBJECTIVE
  To identify factors related to patient satisfaction in patients receiving primary care-based buprenorphine/naloxone that varied in counseling intensity (20 vs 45 minutes) and office visit frequency (weekly vs thrice weekly).
  
  
  METHODS
  One hundred and forty-two opioid-dependent subjects.
  
  
  METHODS
  Demographics, drug treatment history, and substance use status at baseline and during treatment were collected. The primary outcome was patient satisfaction at 12 weeks.
  
  
  RESULTS
  Patients' mean overall satisfaction score was 4.4 (out of 5). Patients were most satisfied with the medication and ancillary services and indicated strong willingness to refer a substance-abusing friend for the same treatment. Patients were least satisfied with their interactions with other opioid-dependent patients, referrals to Narcotics Anonymous, and the inconvenience of the treatment location. Female gender (beta = .17, P = .04) and non-White ethnicity/race (beta = .17, P = .04) independently predicted patient satisfaction. Patients who received briefer counseling and buprenorphine/naloxone dispensed weekly had greater satisfaction than those whose medication was dispensed thrice weekly (mean difference 4.9, 95% confidence interval 0.08 to 9.80, P = .03).
  
  
  CONCLUSIONS
  Patients are satisfied with primary care office-based buprenorphine/naloxone. Providers should consider the identified barriers to patient satisfaction.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519-1187, USA, declan.barry@yale.edu
authors.forename: Declan T
authors.initials: DT
authors.lastname: Barry
authors.forename: Brent A
authors.initials: BA
authors.lastname: Moore
authors.forename: Michael V
authors.initials: MV
authors.lastname: Pantalon
authors.forename: Marek C
authors.initials: MC
authors.lastname: Chawarski
authors.forename: Lynn E
authors.initials: LE
authors.lastname: Sullivan
authors.forename: Patrick G
authors.initials: PG
authors.lastname: O'Connor
authors.forename: Richard S
authors.initials: RS
authors.lastname: Schottenfeld
authors.forename: David A
authors.initials: DA
authors.lastname: Fiellin
mesh_terms: D000328:Adult; D002047:Buprenorphine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage*; D009819:Office Visits; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000453:epidemiology; D017060:Patient Satisfaction; D011320:Primary Health Care / Q000379:methods; D016896:Treatment Outcome
chemical_list: D009270:Naloxone; D002047:Buprenorphine